Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SALUTENSIN vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Salutensin is a combination of two antihypertensive agents: hydroflumethiazide, a thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption; and reserpine, a Rauwolfia alkaloid that depletes catecholamines (norepinephrine, dopamine) from presynaptic nerve terminals by irreversibly blocking vesicular monoamine transporter (VMAT), leading to decreased peripheral vasoconstriction and heart rate.
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Hypertension
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
Oral, 1 tablet (50 mg spironolactone + 5 mg bendroflumethiazide) once daily. Maximum 2 tablets per day.
250 mg orally twice daily
Terminal elimination half-life: 18-24 hours (mean 20 h); clinically, requires 5-7 days to reach steady state; prolonged in renal impairment (Cr Cl <30 m L/min: up to 40 h) and in elderly.
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Hydroflumethiazide: not extensively metabolized, mainly excreted unchanged in urine. Reserpine: extensively metabolized in the liver via hydrolysis and conjugation, with metabolites excreted in urine and feces.
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Primarily renal (65-75% as unchanged drug); biliary/fecal (20-30%) with enterohepatic recirculation; minor metabolism via CYP3A4 to inactive metabolites.
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
98% bound to albumin and α1-acid glycoprotein; binding is concentration-independent; altered in hypoalbuminemia.
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
0.15-0.25 L/kg (approx. 10-18 L in 70 kg adult); indicates moderate tissue distribution; Vd increased in hypertension (0.3 L/kg) and decreased in heart failure.
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Oral: 85-95% due to extensive absorption and minimal first-pass metabolism; food delays absorption but does not reduce extent; IV and IM: 100%.
70-90% (oral); 100% (IV).
Contraindicated if GFR <30 m L/min. If GFR 30-50 m L/min, reduce dose to half tablet daily and monitor potassium; avoid if potassium >5.5 mmol/L.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
Contraindicated in Child-Pugh class C. In class A or B, use with caution; start at half tablet daily and monitor hepatic function.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
Not recommended for children under 18 years due to lack of safety data.
Not recommended for use in pediatric patients due to lack of safety and efficacy data
Start at half tablet daily (25 mg spironolactone + 2.5 mg bendroflumethiazide). Monitor renal function, electrolytes, and blood pressure closely. Avoid if creatinine clearance <30 m L/min.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
Reserpine may cause mental depression. Therapy should be discontinued at the first sign of depression (e.g., despondency, early morning insomnia, loss of appetite, impotence). Depressive reactions are more common in patients with a history of depression.
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
Electrolyte imbalance (hypokalemia, hyponatremia), hypotension, drowsiness/sedation, depression risk, exacerbation of peptic ulcer or ulcerative colitis, use caution in renal/hepatic impairment, and avoid abrupt discontinuation (reserpine may cause withdrawal syndrome).
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
Hypersensitivity to thiazides, reserpine, or sulfonamides; anuria or severe renal impairment; history of mental depression; active peptic ulcer; ulcerative colitis; pheochromocytoma; electroconvulsive therapy; concurrent MAO inhibitor therapy.
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
Avoid high-sodium foods as they may reduce antihypertensive effect. Limit alcohol intake due to additive blood pressure lowering and dizziness risk. Ensure adequate potassium intake (e.g., bananas, oranges) unless contraindicated by renal function.
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
First trimester: Limited human data; based on animal studies, possible increased risk of congenital anomalies including cardiovascular and renal defects. Second and third trimesters: Risk of fetal hypotension, decreased placental perfusion, oligohydramnios, and neonatal renal dysfunction or failure. Avoid use in pregnancy unless no alternative.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
Excreted into breast milk; M/P ratio not established. Potential for adverse effects in nursing infant (hypotension, bradycardia). Use with caution, monitor infant for signs of hypotension.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
No specific dose adjustment studies; pregnancy may alter pharmacokinetics (increased volume of distribution, decreased plasma protein binding). Monitor therapeutic response and toxicity closely; consider dose titration based on blood pressure.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
SALUTENSIN is a combination of hydrochlorothiazide and reserpine. Monitor for hypokalemia and hyperuricemia due to thiazide; reserpine may cause nasal congestion and depression. Avoid in patients with history of depression or peptic ulcer. Use with caution in renal impairment (Cr Cl <30 m L/min).
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Take this medication exactly as prescribed, usually once daily in the morning to avoid nocturia.,Avoid sudden discontinuation; consult your doctor before stopping.,Report symptoms of depression, unusual mood changes, or nasal congestion to your healthcare provider.,This drug may cause dizziness or drowsiness; avoid driving until you know how it affects you.,Monitor for signs of low potassium (muscle cramps, weakness, irregular heartbeat) or high uric acid (joint pain, swelling).
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SALUTENSIN vs ALDOCLOR-250, answered by our medical review team.
SALUTENSIN is a Antihypertensive Combination that works by Salutensin is a combination of two antihypertensive agents: hydroflumethiazide, a thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption; and reserpine, a Rauwolfia alkaloid that depletes catecholamines (norepinephrine, dopamine) from presynaptic nerve terminals by irreversibly blocking vesicular monoamine transporter (VMAT), leading to decreased peripheral vasoconstriction and heart rate.. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SALUTENSIN and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SALUTENSIN is: Oral, 1 tablet (50 mg spironolactone + 5 mg bendroflumethiazide) once daily. Maximum 2 tablets per day.. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SALUTENSIN and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SALUTENSIN is classified as Category C. First trimester: Limited human data; based on animal studies, possible increased risk of congenital anomalies including cardiovascular and renal defects. Second and third trimester. ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.